﻿<?xml version="1.0" encoding="utf-8"?><rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/"><channel><title>Cision News</title><link>https://news.cision.com</link><description>Cision is the leading global provider of media research, distribution, monitoring and evaluation services. With over 40 locations throughout the world, Cision provides the insight, expertise and intelligence that improve performance and build reputations.</description><pubDate>Tue, 09 Jun 2026 20:36:01 GMT</pubDate><image><title>Cision News</title><width>146</width><height>60</height><link>https://news.cision.com</link><url>https://news.cision.com/Content/img/news-logo.png</url></image><item><title>Axcentua closes double-digit million (SEK) Series-A Financing Round</title><link>http://news.cision.com/axcentua/r/axcentua-closes-double-digit-million--sek--series-a-financing-round,c451428</link><guid isPermaLink="false">cision240597</guid><description><![CDATA[Axcentua Pharmaceuticals AB closed its series-A financing round led by the entrepreneur William Gunnarsson, the former CEO and co-founder of Orphan Europe that now is part of the Recordati Group (Ticker REC). The financing will enable Axcentua to advance its multi-targeted lead small molecule AXP107-11 into clinical trials. The compound is intended for use as a combination therapy of different difficult-to-treat tumors such as pancreatic, liver, lung and prostate cancer. By applying the company’s unique crystal re-engineering strategy, AXP107-11 has been developed in less than 2 years to a]]></description><pubDate>Thu, 08 Oct 2009 09:49:16 GMT</pubDate></item></channel></rss>